CRSP CRISPR: Rasio rega marang prakiraan pendapatan

Simbol resmi perusahaan CRISPR Therapeutics (CRSP)

The forward price-to-sales valuation trend shows that the parameter reaches 155.70. Management under Samarthit Chatterjee has successfully launched the first gene therapy on the market while maintaining high liquidity for CRISPR Therapeutics AG (CRSP). Asset value growth now relies on the implementation of Casgevy and achievements in immuno-oncology. A strategic alliance with pharmaceutical behemoths provides scientific synergy and capital for the development of DNA technologies.

CRISPR Therapeutics - Multiplikator Forward P/S CRSP (periode 04.07.2022 - 17.11.2026)

CRSP (CRISPR Therapeutics): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:
Analisis fundamental perusahaan:CRISPR Therapeutics (CRSP)
Sampel barang crisprtx.com

The forward P/S ratio assesses the market value of an asset relative to expected revenue, allowing investors to determine the extent of the premium paid for future cash flows. By analyzing the expected P/S chart for CRISPR Therapeutics AG (CRSP), one can evaluate how effectively the capitalization reflects the potential of the R&D core, comprised of elite geneticists whose DNA editing developments determine the long-term commercial value of the business.

Perusahaan pesaing

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator Forward P/S|Multiplikator Forward P/S Beam Therapeutics Inc.|Rasio rega marang prakiraan pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Kapitalisasi marang prakiraan pendapatan|10x Genomics Inc - Multiplikator forward rega marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.